Caribou Biosciences, Inc. (CRBU)

NMS – Цена в реальном времени. Валюта: USD

1.68

+0.11 (7.01%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.66

-0.02 (-1.19%)

После закрытия: Jun 26, 2026, 7:06 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Caribou Biosciences, Inc. (CRBU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears

Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Видео

No Data

Пресс-релизы

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Search stocks

Caribou Biosciences, Inc. (CRBU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears

Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Видео

No Data

Пресс-релизы

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update